*SCALPSWINGSTRADDLE*

[THE_YAK]

MDVN MDV3100 for prostate cancer positive shows positive survival data

Medivation and Astellas Pharma announced positive Independent Data Monitoring Committee results from a planned interim analysis of the Phase 3 AFFIRM trial of MDV3100 in men with advanced prostate cancer previously treated with chemotherapy. MDV3100 successfully met the study's pre-specified interim efficacy stopping criteria, demonstrating a clinically meaningful and statistically significant improvement in overall survival compared to placebo. MDV3100 produced a 4.8-month advantage in median overall survival compared to placebo. MDV3100 provided a 37 percent reduction in risk of death compared to placebo